Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
IMF Forecasts Global Inflation Decline as Growth Remains Resilient 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
